Strategies for Cancer Vaccine Development

Treating cancer with vaccines has been a challenging field of investigation since the 1950s. Over the years, the lack of effective active immunotherapies has led to the development of numerous novel strategies. However, the use of therapeutic cancer vaccines may be on the verge of becoming an effect...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2010-01, Vol.2010 (2010), p.1-13
Main Authors: Huen, Ngar-Yee, Schlom, Jeffrey, Tsang, Kwong Y., Vergati, Matteo, Intrivici, Chiara
Format: Article
Language:English
Subjects:
Animals
Biotechnology
Cancer therapies
Cancer Vaccines
Clinical Trials as Topic
Humans
Medical research
Mortality
Prostate cancer
Review
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c562t-d4c30aaf3172fb2889f7dfd3bab5e07e1e02382266f2da26f639da5b2e81eab33
cites cdi_FETCH-LOGICAL-c562t-d4c30aaf3172fb2889f7dfd3bab5e07e1e02382266f2da26f639da5b2e81eab33
container_end_page 13
container_issue 2010
container_start_page 1
container_title BioMed research international
container_volume 2010
creator Huen, Ngar-Yee
Schlom, Jeffrey
Tsang, Kwong Y.
Vergati, Matteo
Intrivici, Chiara
description Treating cancer with vaccines has been a challenging field of investigation since the 1950s. Over the years, the lack of effective active immunotherapies has led to the development of numerous novel strategies. However, the use of therapeutic cancer vaccines may be on the verge of becoming an effective modality. Recent phase II/III clinical trials have achieved hopeful results in terms of overall survival. Yet despite these encouraging successes, in general, very little is known about the basic immunological mechanisms involved in vaccine immunotherapy. Gaining a better understanding of the mechanisms that govern the specific immune responses (i.e., cytotoxic T lymphocytes, CD4 T helper cells, T regulatory cells, cells of innate immunity, tumor escape mechanisms) elicited by each of the various vaccine platforms should be a concern of cancer vaccine clinical trials, along with clinical benefits. This review focuses on current strategies employed by recent clinical trials of therapeutic cancer vaccines and analyzes them both clinically and immunologically.
doi_str_mv 10.1155/2010/596432
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2914453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2287917451</sourcerecordid><originalsourceid>FETCH-LOGICAL-c562t-d4c30aaf3172fb2889f7dfd3bab5e07e1e02382266f2da26f639da5b2e81eab33</originalsourceid><addsrcrecordid>eNqF0UtLAzEUBeAgiu-Va6W4EZVqcvOcjSD1CQUXPrYhM3Njp0xnajKt-O-dMlrUjasE8nGSm0PIHqNnjEl5DpTRc5kowWGFbDLGaF-DZKvLveAbZCvGMaVMG5Wskw2gmirFYJMcPzbBNfhaYOz5OvQGrsow9F5clhUV9q5wjmU9nWDV7JA178qIu1_rNnm-uX4a3PWHD7f3g8thP5MKmn4uMk6d85xp8CkYk3id-5ynLpVINTKkwA2AUh5yB8ornuROpoCGoUs53yYXXe50lk4wz9qrgyvtNBQTFz5s7Qr7-6QqRva1nltImBByEXD0FRDqtxnGxk6KmGFZugrrWbRGSmW0UPCv1MIkwoBKWnn4R47rWajaf2jjFNOUigU67VAW6hgD-uWjGbWLquyiKttV1eqDn3Mu7Xc3LTjpwKiocvde_JO232FsCXq3xMJwQxX_BIgoo8E</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>856170049</pqid></control><display><type>article</type><title>Strategies for Cancer Vaccine Development</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Huen, Ngar-Yee ; Schlom, Jeffrey ; Tsang, Kwong Y. ; Vergati, Matteo ; Intrivici, Chiara</creator><contributor>Xiao, Zhengguo</contributor><creatorcontrib>Huen, Ngar-Yee ; Schlom, Jeffrey ; Tsang, Kwong Y. ; Vergati, Matteo ; Intrivici, Chiara ; Xiao, Zhengguo</creatorcontrib><description>Treating cancer with vaccines has been a challenging field of investigation since the 1950s. Over the years, the lack of effective active immunotherapies has led to the development of numerous novel strategies. However, the use of therapeutic cancer vaccines may be on the verge of becoming an effective modality. Recent phase II/III clinical trials have achieved hopeful results in terms of overall survival. Yet despite these encouraging successes, in general, very little is known about the basic immunological mechanisms involved in vaccine immunotherapy. Gaining a better understanding of the mechanisms that govern the specific immune responses (i.e., cytotoxic T lymphocytes, CD4 T helper cells, T regulatory cells, cells of innate immunity, tumor escape mechanisms) elicited by each of the various vaccine platforms should be a concern of cancer vaccine clinical trials, along with clinical benefits. This review focuses on current strategies employed by recent clinical trials of therapeutic cancer vaccines and analyzes them both clinically and immunologically.</description><identifier>ISSN: 1110-7243</identifier><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 1110-7251</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2010/596432</identifier><identifier>PMID: 20706612</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Puplishing Corporation</publisher><subject>Animals ; Biotechnology ; Cancer therapies ; Cancer Vaccines ; Clinical Trials as Topic ; Humans ; Medical research ; Mortality ; Prostate cancer ; Review ; Tumors</subject><ispartof>BioMed research international, 2010-01, Vol.2010 (2010), p.1-13</ispartof><rights>Copyright © 2010</rights><rights>Copyright © 2010 Matteo Vergati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2010 Matteo Vergati et al. 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c562t-d4c30aaf3172fb2889f7dfd3bab5e07e1e02382266f2da26f639da5b2e81eab33</citedby><cites>FETCH-LOGICAL-c562t-d4c30aaf3172fb2889f7dfd3bab5e07e1e02382266f2da26f639da5b2e81eab33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/856170049/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/856170049?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25733,27903,27904,36991,44569,53769,53771,74872</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20706612$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Xiao, Zhengguo</contributor><creatorcontrib>Huen, Ngar-Yee</creatorcontrib><creatorcontrib>Schlom, Jeffrey</creatorcontrib><creatorcontrib>Tsang, Kwong Y.</creatorcontrib><creatorcontrib>Vergati, Matteo</creatorcontrib><creatorcontrib>Intrivici, Chiara</creatorcontrib><title>Strategies for Cancer Vaccine Development</title><title>BioMed research international</title><addtitle>J Biomed Biotechnol</addtitle><description>Treating cancer with vaccines has been a challenging field of investigation since the 1950s. Over the years, the lack of effective active immunotherapies has led to the development of numerous novel strategies. However, the use of therapeutic cancer vaccines may be on the verge of becoming an effective modality. Recent phase II/III clinical trials have achieved hopeful results in terms of overall survival. Yet despite these encouraging successes, in general, very little is known about the basic immunological mechanisms involved in vaccine immunotherapy. Gaining a better understanding of the mechanisms that govern the specific immune responses (i.e., cytotoxic T lymphocytes, CD4 T helper cells, T regulatory cells, cells of innate immunity, tumor escape mechanisms) elicited by each of the various vaccine platforms should be a concern of cancer vaccine clinical trials, along with clinical benefits. This review focuses on current strategies employed by recent clinical trials of therapeutic cancer vaccines and analyzes them both clinically and immunologically.</description><subject>Animals</subject><subject>Biotechnology</subject><subject>Cancer therapies</subject><subject>Cancer Vaccines</subject><subject>Clinical Trials as Topic</subject><subject>Humans</subject><subject>Medical research</subject><subject>Mortality</subject><subject>Prostate cancer</subject><subject>Review</subject><subject>Tumors</subject><issn>1110-7243</issn><issn>2314-6133</issn><issn>1110-7251</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqF0UtLAzEUBeAgiu-Va6W4EZVqcvOcjSD1CQUXPrYhM3Njp0xnajKt-O-dMlrUjasE8nGSm0PIHqNnjEl5DpTRc5kowWGFbDLGaF-DZKvLveAbZCvGMaVMG5Wskw2gmirFYJMcPzbBNfhaYOz5OvQGrsow9F5clhUV9q5wjmU9nWDV7JA178qIu1_rNnm-uX4a3PWHD7f3g8thP5MKmn4uMk6d85xp8CkYk3id-5ynLpVINTKkwA2AUh5yB8ornuROpoCGoUs53yYXXe50lk4wz9qrgyvtNBQTFz5s7Qr7-6QqRva1nltImBByEXD0FRDqtxnGxk6KmGFZugrrWbRGSmW0UPCv1MIkwoBKWnn4R47rWajaf2jjFNOUigU67VAW6hgD-uWjGbWLquyiKttV1eqDn3Mu7Xc3LTjpwKiocvde_JO232FsCXq3xMJwQxX_BIgoo8E</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Huen, Ngar-Yee</creator><creator>Schlom, Jeffrey</creator><creator>Tsang, Kwong Y.</creator><creator>Vergati, Matteo</creator><creator>Intrivici, Chiara</creator><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20100101</creationdate><title>Strategies for Cancer Vaccine Development</title><author>Huen, Ngar-Yee ; Schlom, Jeffrey ; Tsang, Kwong Y. ; Vergati, Matteo ; Intrivici, Chiara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c562t-d4c30aaf3172fb2889f7dfd3bab5e07e1e02382266f2da26f639da5b2e81eab33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Biotechnology</topic><topic>Cancer therapies</topic><topic>Cancer Vaccines</topic><topic>Clinical Trials as Topic</topic><topic>Humans</topic><topic>Medical research</topic><topic>Mortality</topic><topic>Prostate cancer</topic><topic>Review</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huen, Ngar-Yee</creatorcontrib><creatorcontrib>Schlom, Jeffrey</creatorcontrib><creatorcontrib>Tsang, Kwong Y.</creatorcontrib><creatorcontrib>Vergati, Matteo</creatorcontrib><creatorcontrib>Intrivici, Chiara</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huen, Ngar-Yee</au><au>Schlom, Jeffrey</au><au>Tsang, Kwong Y.</au><au>Vergati, Matteo</au><au>Intrivici, Chiara</au><au>Xiao, Zhengguo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Strategies for Cancer Vaccine Development</atitle><jtitle>BioMed research international</jtitle><addtitle>J Biomed Biotechnol</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>2010</volume><issue>2010</issue><spage>1</spage><epage>13</epage><pages>1-13</pages><issn>1110-7243</issn><issn>2314-6133</issn><eissn>1110-7251</eissn><eissn>2314-6141</eissn><abstract>Treating cancer with vaccines has been a challenging field of investigation since the 1950s. Over the years, the lack of effective active immunotherapies has led to the development of numerous novel strategies. However, the use of therapeutic cancer vaccines may be on the verge of becoming an effective modality. Recent phase II/III clinical trials have achieved hopeful results in terms of overall survival. Yet despite these encouraging successes, in general, very little is known about the basic immunological mechanisms involved in vaccine immunotherapy. Gaining a better understanding of the mechanisms that govern the specific immune responses (i.e., cytotoxic T lymphocytes, CD4 T helper cells, T regulatory cells, cells of innate immunity, tumor escape mechanisms) elicited by each of the various vaccine platforms should be a concern of cancer vaccine clinical trials, along with clinical benefits. This review focuses on current strategies employed by recent clinical trials of therapeutic cancer vaccines and analyzes them both clinically and immunologically.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Puplishing Corporation</pub><pmid>20706612</pmid><doi>10.1155/2010/596432</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1110-7243
ispartof BioMed research international, 2010-01, Vol.2010 (2010), p.1-13
issn 1110-7243
2314-6133
1110-7251
2314-6141
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2914453
source Wiley Online Library Open Access; Publicly Available Content Database; PubMed Central
subjects Animals
Biotechnology
Cancer therapies
Cancer Vaccines
Clinical Trials as Topic
Humans
Medical research
Mortality
Prostate cancer
Review
Tumors
title Strategies for Cancer Vaccine Development
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T12%3A59%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Strategies%20for%20Cancer%20Vaccine%20Development&rft.jtitle=BioMed%20research%20international&rft.au=Huen,%20Ngar-Yee&rft.date=2010-01-01&rft.volume=2010&rft.issue=2010&rft.spage=1&rft.epage=13&rft.pages=1-13&rft.issn=1110-7243&rft.eissn=1110-7251&rft_id=info:doi/10.1155/2010/596432&rft_dat=%3Cproquest_pubme%3E2287917451%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c562t-d4c30aaf3172fb2889f7dfd3bab5e07e1e02382266f2da26f639da5b2e81eab33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=856170049&rft_id=info:pmid/20706612&rfr_iscdi=true